Ren-Wang Peng

20PUBLICATIONS
29CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical biochemistry - lipidsMedical infection agents (incl. prions)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jan 16, 2026
Correction to: De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.

Duo Xu, Yanyun Gao, Shengchen Liu

|Aug 11, 2025
Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma.

Yantang Lin, Christelle Dubey, Tereza Losmanova

|Jul 24, 2025
De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.

Duo Xu, Yanyun Gao, Shengchen Liu

|Mar 17, 2025
Ubiquinol-mediated suppression of mitochondria-associated ferroptosis is a targetable function of lactate dehydrogenase B in cancer.

Haibin Deng, Liang Zhao, Huixiang Ge

|Dec 06, 2024
Lactate dehydrogenase B noncanonically promotes ferroptosis defense in KRAS-driven lung cancer.

Liang Zhao, Haibin Deng, Jingyi Zhang

|Jan 26, 2024
CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research.

Xian Gong, Jianting Du, Ren-Wang Peng

Pageof 4

Frequent Collaborators

9 joint publications

Thomas Michael Marti

9 joint publications

Ralph A Schmid

8 joint publications

Haitang Yang

6 joint publications

Patrick Dorn